BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T044437
CREATED:20250905T112712Z
LAST-MODIFIED:20250905T112817Z
UID:41881-1764633600-1764806399@www.pharmajournalist.com
SUMMARY:Designing the AI-Enabled Biopharma Workforce Summit
DESCRIPTION:The World’s Only Industry-Specific Forum on AI-Oriented Skills-Centric Workforce Transformation in Life Sciences\nMost roles in biopharma organizations will undergo an AI-driven transformation in the coming years. But exactly how that transformation manifests itself\, in what jobs\, with what skills\, and across what proportion of our workforces is not yet fully clear. \nWhat is clear\, though\, is that the future depends on what we do now. The most forward-thinking companies already know that innovation doesn’t just happen at the bench\, it also takes place company-wide in working out what needs to be done\, how\, and by whom. \nThey are building future workforce capability faster by reassessing the needs of each department and fundamentally rethinking what work is best done by people versus what can be automated with technology. For the first time\, this forum will shine a light on how this is done. \nTaking part will help you approach organizational design with a new perspective which is skills centric\, rather than job centric and allow you to walk away with a new skills taxonomy that will help you deliver more productivity and more innovation from fewer people in less time. \nDownload the Agenda
URL:http://www.pharmajournalist.com/event/designing-the-ai-enabled-biopharma-workforce-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T044437
CREATED:20250820T123645Z
LAST-MODIFIED:20250820T123645Z
UID:41743-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:7th Cell Therapy Analytical Development Summit
DESCRIPTION:Recognized as the industry’s leading forum for cell therapy analytical\, quality control\, assay\, and CMC professionals\, the 7th Cell Therapy Analytical Development Summit\, returns to Boston to provide the expertise needed to prepare your teams for clinical and commercial readiness. Hear directly 80+ experts from Takeda\, Arsenal Bio\, Bayer\, Genentech\, Adicet Bio\, Quell Therapeutics\, and the National Institute of Health\, as they share proven strategies\, innovative technologies and best-in-class approaches to enhance your product safety and quality\, ahead of regulatory approval. \nNow combined with the previously separate\, Cell Therapy Potency Assay Summit\, this meeting provides you with an even more comprehensive agenda\, covering the full landscape of analytical development\, across early- and late-stage assay development tracks. Join us this December to fast-track the next era of safe\, potent and robust cell therapies to market! \nFor more information\, please visit https://ter.li/9uagdj
URL:http://www.pharmajournalist.com/event/7th-cell-therapy-analytical-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251204
DTSTAMP:20260515T044438
CREATED:20250812T105107Z
LAST-MODIFIED:20250812T105107Z
UID:41720-1764547200-1764806399@www.pharmajournalist.com
SUMMARY:9th Complement-Based Drug Development Summit
DESCRIPTION:Diving Into the Complement Cascade to Explore Intervention Points\, Harnessing Biomarker Strategies to Identify Optimal Patient Populations\, & Exploring the Therapeutic Opportunity from Rare Disease to Inflammation to Autoimmune Disease. \nSo far\, 2025 has brought significant excitement and progress to the complement-based therapeutic landscape. Leading biopharma companies like Novartis\, Annexon Biosciences and Omeros\, are making significant clinical progress in PNH\, AMD\, IgAN and C3G\, whilst key academics such as Michael Holers\, Michael Brenner\, and Brahm Segal continue to make discoveries in complement imaging\, novel pathways\, and new therapeutics areas such as oncology and transplantation. \nThe Complement-Based Drug Development Summit returns for its 9th year to unite the leading experts in complement biology and therapeutic development\, from innovative biotech to impactful large pharma and academic experts. This meeting will harness the energy and dedication deepening the current understanding of the complement system to advance drug development in rare disease and beyond with patients at the forefront. \nJoin us at the 2025 meeting to gain insights from 20+ expert speakers covering the end-to-end complement-based drug development\, from basic biology to diagnostics and clinical development. \nParticipate in three dedicated workshops for active discussion on key topics including the intracellular complement system\, bispecific complement mediators\, and innovative delivery of complement-based therapeutics to ensure delivery to the correct targets. \nThis comprehensive program spans a broad spectrum of renal\, ophthalmic\, neurological\, and haematological indications\, mirroring the shift in focus of the complement field from rare orphan indications to larger patient populations. \nJoin 80+ industry experts this December and access exclusive insights into therapeutic development across the complement field and bring actionable learnings and competitive intelligence back to your team.
URL:http://www.pharmajournalist.com/event/9th-complement-based-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T044438
CREATED:20250829T114330Z
LAST-MODIFIED:20250829T114330Z
UID:41806-1763510400-1763683199@www.pharmajournalist.com
SUMMARY:3rd Donor Selection & Cell Source Summit
DESCRIPTION:Returning for its third year\, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused exclusively on the strategic and scientific challenges of donor selection and cell sourcing for allogeneic therapies. \nThis summit brings together leading minds from biopharma\, blood banks\, apheresis providers\, and cell therapy innovators to address one of the most critical bottlenecks in the development of scalable\, off-the-shelf treatments. \nWith over 600 allogeneic clinical trials currently underway\, the pressure to secure high-quality\, consistent donor-derived starting material has never been greater. This summit provides a unique opportunity to explore how smarter donor screening\, recruitment\, and retention strategies can directly impact product quality\, manufacturing scalability\, and clinical success. \nAttendees will gain actionable insights into: \n\nDonor testing and screening protocols that improve product safety and consistency\nRetention strategies to build reliable donor pools\nCryobiology and supply chain innovations that enhance cell viability and streamline logistics\nAnalytical development and quality control for robust characterization of starting material\n\nSee what other insights you can walk-away with in the program: https://ter.li/c2h7ym \nThe summit features expert speakers from leading organizations including Bristol Myers Squibb\, Genentech\, Allogene Therapeutics\, ImmuneBridge\, NKILT\, Luminary Therapeutics\, and many more offering a cross-functional perspective on how donor and source decisions shape the future of cell therapy. \nUnlike broader cell therapy conferences\, this event zeroes in on the upstream decisions that define downstream success. Whether you’re optimizing donor engagement\, navigating regulatory complexities\, or refining your sourcing strategy\, the Donor Selection & Cell Source Summit provides the tools and connections to move your program forward. \nExpect two days of deep scientific exchange\, strategic discussion\, and collaborative problem-solving in an intimate setting designed to foster meaningful dialogue. If you’re working to unlock the full potential of allogeneic therapies\, this is the one event you can’t afford to miss. \nFor more information on the summit\, view the program: https://ter.li/dc18d1
URL:http://www.pharmajournalist.com/event/3rd-donor-selection-cell-source-summit/
LOCATION:Westin Bayview San Diego\, 1051 Columbia St\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T044438
CREATED:20250912T125210Z
LAST-MODIFIED:20250912T130631Z
UID:41941-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:9th Dermatology Drug Development Summit
DESCRIPTION:The 9th Dermatology Drug Development Summit is the definitive industry-led forum bringing together a driven community of experts pioneering innovative drug discovery and clinical strategies to improve long-term outcomes for patients with immuno-inflammatory disease. With disease heterogeneity and biomarker discovery fueling a new wave of research\, and clinical pipelines facing intensifying competition\, the need to develop differentiated\, novel candidates has never been more critical. \nAs the field accelerates with clinical and commercial momentum\, highlighted by Sanofi’s continued success with Dupixent\, Corvus’ promising Phase 1 data on Soquelitinib\, and landmark deals such as Gilead’s $1.7B inflammation partnership with LEO Pharma – this summit provides an essential platform to stay ahead of the curve. Returning this November\, the meeting unites 120+ leading experts from pharma\, biotech\, and academia\, all dedicated to overcoming the most pressing R&D bottlenecks in dermatology drug development. \nAttendees will gain insights into the latest preclinical and clinical findings across both rare and common conditions\, including atopic dermatitis\, psoriasis\, hidradenitis suppurativa\, vitiligo\, pemphigus nodularis\, bullous pemphigoid\, and alopecia areata. Sessions will explore the complexity of disease heterogeneity\, emerging mechanisms of action\, safety considerations\, and the evolving regulatory landscape. With contributions from thought leaders at AbbVie\, Sanofi\, Takeda\, Incyte\, Merck\, and other trailblazing organizations\, discussions will span discovery\, preclinical\, translational\, clinical\, and medical affairs perspectives. \nThe program also offers a forward-looking exploration of the modalities reshaping dermatology pipelines\, from bispecifics and biologics to oligonucleotides and beyond. By combining cutting-edge science with real-world clinical and strategic insights\, the 9th Dermatology Drug Development Summit equips participants with the tools to accelerate innovation\, navigate increasing competition\, and ultimately deliver therapies that transform patient quality of life. \nIf you’d like to learn more about the summit\, download the event guide or get in touch!
URL:http://www.pharmajournalist.com/event/9th-dermatology-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T044438
CREATED:20250829T120700Z
LAST-MODIFIED:20250829T120700Z
UID:41824-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:7th Myeloid-Directed Therapies Summit
DESCRIPTION:The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology\, Inflammation and Beyond… \nUniting leading experts from pharma\, biotech\, and academia\, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells\, this forum dives into myeloid reprogramming\, cell state heterogeneity\, and translational challenges to unlock next-generation immune modulation. \nWith breakthrough insights from Eli Lilly\, AbbVie\, Pfizer\, AstraZeneca\, and Faron Pharmaceuticals\, and cutting-edge academic labs\, this is your opportunity to explore clinical case studies\, dissect failed monotherapy lessons\, and gain clarity on patient stratification\, trial design\, and combination strategies. \nLearn more: https://ter.li/by8e82
URL:http://www.pharmajournalist.com/event/7th-myeloid-directed-therapies-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T044438
CREATED:20250731T103150Z
LAST-MODIFIED:20250731T103150Z
UID:41605-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:3rd LNP Characterization & Analytical Development Summit
DESCRIPTION:3rd LNP Characterization & Analytical Development Summit\nDe-Risk Regulatory Submissions Through Smarter LNP Characterization \nCurated in collaboration with leading analytical scientists and key LNP stakeholders\, the 3rd LNP Characterization & Analytical Development Summit returns with new data\, fresh insights\, and an expanded speaker lineup. As the definitive forum for LNP analytics and characterization\, this summit is your go-to platform for driving the development of safe\, effective\, and high-quality LNP-based drug products. \nThis highly focused\, three-day agenda will equip analytical experts with the technical insights needed to: \n\nAccelerate development timelines\nBridge critical analytical gaps\nStreamline regulatory submissions for faster approval\n\nJoin over 90 industry leaders in analytics\, characterization\, assays\, and CMC from organizations including Pfizer\, Novo Nordisk\, Prime Medicine\, Tessera Therapeutics\, GSK\, Sanofi\, and more. \nKey Benefits of Attending: \n\nGain deep technical knowledge on cutting-edge LNP analytics\nDiscover strategies to overcome common characterization challenges\nAlign on regulatory expectations to support faster\, smoother submissions\nNetwork with peers tackling the same development and regulatory hurdles\n\nWith data-driven presentations and expert-led discussions\, this is your opportunity to help define and implement robust analytical strategies that support the rapid development and approval of next-generation genomic medicines. \nLearn more here: https://ter.li/ympfix
URL:http://www.pharmajournalist.com/event/3rd-lnp-characterization-analytical-development-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251118
DTEND;VALUE=DATE:20251121
DTSTAMP:20260515T044438
CREATED:20250731T102550Z
LAST-MODIFIED:20250731T102550Z
UID:41600-1763424000-1763683199@www.pharmajournalist.com
SUMMARY:Model-Informed Drug Development Summit
DESCRIPTION:With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing\, regulatory change is accelerating\, solidifying Model-Informed Drug Development (MIDD) as a critical\, non-negotiable tool in the drug development process. \nThe Model-Informed Drug Development Summit is the first and only industry-focused\, 3-day strategic meeting dedicated to exploring how MIDD is transforming decision-making and driving drug development success. This is your opportunity to benchmark against industry leaders\, refine your strategy\, and future-proof your development approach. \nJoin senior experts in pharmacometrics\, clinical pharmacology\, PK/PD\, and modeling from leading organizations including Pfizer\, Third Rock Ventures\, Johnson & Johnson\, AbbVie\, and more\, as they uncover how MIDD is being used to: \n\nSelect better candidates earlier in development\nStreamline or eliminate clinical trial phases\nPersonalize and optimize trial designs\nBuild stronger\, data-driven regulatory submissions\n\nWhy Attend? \n\nUnlock real-world case studies showing how MIDD accelerates timelines\, cuts costs\, and improves outcomes\nGain insight into how peers are implementing MIDD from discovery through to regulatory approval\nCollaborate with cross-functional teams to exchange strategies and overcome shared challenges\n\nWith exclusive insights into ICH M15\, practical applications across diverse therapeutic areas\, and proven examples of success\, this summit is your one-stop shop for unleashing the full potential of MIDD. \nLearn more here: https://ter.li/unljt8
URL:http://www.pharmajournalist.com/event/model-informed-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251117
DTEND;VALUE=DATE:20251120
DTSTAMP:20260515T044438
CREATED:20250905T113422Z
LAST-MODIFIED:20250905T113422Z
UID:41887-1763337600-1763596799@www.pharmajournalist.com
SUMMARY:9th Antifibrotic Drug Development Summit
DESCRIPTION:2025 has seen a wave of positive anti-fibrosis advances. From Agomab’s Phase 2a results in fibrostenosing Crohn’s\, Boehringer’s Phase 3 IPF data\, Stanford’s TGF-β work in cardiovascular fibrosis\, to over $3B in deals from Lilly\, GSK\, and others\, it’s clear the antifibrotic drug development landscape is undergoing a seismic shift. \nThat’s why this year’s Antifibrotic Drug Development Summit is THE place to be this November.  Learn from the industry’s premier experts at the forefront of fibrosis research\, gain unmissable cross-fibrosis insights\, and make unmatched connections with 80+ industry leaders from Pfizer\, Eli Lilly\, Novartis\, Takeda and more! \nAccess this year’s incredible lineup of speakers \nJoin us this year to: \n\nUnlock novel targets with advances in single-cell and spatial omics\, immune-stromal interactions\, and cross-tissue mechanisms\, featuring insights from Harvard Medical School\, Gilead Sciences\, and AdaptVac\nStrengthen translational confidence with precision-cut tissue slices\, 3D models\, and AI-driven biomarker strategies to bridge the gap between preclinical promise and clinical success\nDesign winning clinical programs with lessons from recent Phase 2 data\, including Resmetirom’s approval for MASH fibrosis and emerging IPF signals from GRI Bio and Redx Pharma\nNavigate the evolving landscape with expert perspectives on combination therapies\, GLP-1 competition\, and investor priorities to position your pipeline for partnerships and approvals\n\nDon’t miss out – invite your colleagues to join you and take advantage of our early bird rates and group savings! \nSecure my spot
URL:http://www.pharmajournalist.com/event/9th-antifibrotic-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251111
DTEND;VALUE=DATE:20251114
DTSTAMP:20260515T044438
CREATED:20250829T114659Z
LAST-MODIFIED:20250829T114659Z
UID:41812-1762819200-1763078399@www.pharmajournalist.com
SUMMARY:7th TIL Therapies Summit
DESCRIPTION:Now in its seventh year\, the TIL Therapies Summit returns as the leading event dedicated to advancing tumor-infiltrating lymphocytes (TIL) therapies. Taking place November 11–13\, 2025\, in Boston (MA)\, this summit unites global experts across biopharma\, academia\, clinical practice\, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments. \nFollowing the first-ever FDA approval of a TIL therapy in the U.S.\, and with regulatory decisions pending in Canada and Europe\, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection\, engineering\, and manufacturing can unlock scalable\, potent treatments for solid tumors beyond melanoma. \nThe program is designed to tackle the most pressing challenges in TIL development\, including: \n\nEngineering TILs for improved persistence\, potency\, and specificity\nManufacturing innovations in closed systems to speed-up turnaround\, and reduce IL-2 dependency\nClinical trial design and patient access strategies\nBiomarker discovery and potency assay development\nReal-world implementation and patient/provider perspectives\n\nWith 28+ expert speakers\, 50+ attendees\, and 8 hours of dedicated networking\, the summit fosters a collaborative environment for sharing cutting-edge science\, operational insights\, and lived experiences. Attendees will hear from leading voices including: \n\nInge Jedema\, Netherlands Cancer Institute\nJingwei Sun\, Grit Biotechnology\nMadan Jagasia\, Obsidian Therapeutics\nMicah Benson\, KSQ Therapeutics\nMichael Lotze\, University of Pittsburgh\nRoda Amaria\, MD Anderson Cancer Center\n\nYou can see who else is speaking in this year’s program: https://ter.li/i4a730 \nWhether you’re preparing for your first clinical trial\, scaling manufacturing\, or navigating regulatory pathways\, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value. \nUnlike broader cell therapy events\, the TIL Therapies Summit offers a focused\, intimate setting where attendees can engage in meaningful dialogue\, build lasting partnerships\, and stay ahead of the curve in this rapidly evolving space. \nIf you’re committed to transforming the treatment landscape for solid tumors\, the 7th TIL Therapies Summit is your must-attend event for 2025. \nFind out more here: https://ter.li/nfdnks
URL:http://www.pharmajournalist.com/event/7th-til-therapies-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251113
DTSTAMP:20260515T044438
CREATED:20250703T134927Z
LAST-MODIFIED:20250703T134927Z
UID:41451-1762732800-1762991999@www.pharmajournalist.com
SUMMARY:7th Targeted Radiopharmaceuticals Summit Europe
DESCRIPTION:7th Targeted Radiopharmaceuticals Summit Europe \n10–12 November 2025 | Amsterdam \nTranslating Novel Radiopharmaceutical Therapies to Transform the Medical Future \n \nNow in its seventh year\, the Targeted Radiopharmaceuticals Summit Europe returns to Amsterdam to bring together over 200 leaders in radiopharmaceutical therapy development. Designed to establish radiopharmaceuticals as a core pillar of oncology\, this event is essential for professionals working across discovery\, clinical development\, and manufacturing. \nHighlights of the 2025 Program: \nMore than 45 expert speakers from leading companies including Bayer\, AstraZeneca\, Novartis\, Telix Pharmaceuticals\, and more\nIntroduction of a third content track\, covering:\nDiscovery & Preclinical\nTranslational & Clinical\nCMC & Sourcing\nSix in-depth workshops on key challenges including radiopharmaceutical design\, dosimetry translation\, and isotope supply \nKey Speakers: \nThomas Birger Eden-Jensen\, Head\, External Supply Management TRP\, Bayer\nMark Fielding\, Director\, CMC\, Regulatory Affairs\, TRP\, AstraZeneca NEW SPEAKER\nIsabel Jaco\, Group Leader\, RLT Drug Discovery\, Novartis NEW SPEAKER\nSandra Uhlenbroich\, Director\, Discovery\, Bicycle Therapeutics NEW SPEAKER\nFrederic Fantino\, Global Medical Affairs EMEA\, Telix Pharmaceuticals NEW SPEAKER\nThijs Spoor\, Chief Executive Officer\, Perspective Therapeutics NEW SPEAKER\nSigal Kalmanson\, Chief Executive Officer\, Starget Pharma \nTopics Include: \nNovel target discovery\, including SSTR3 and FAP\nIsotope selection and supply chain resilience\nTranslating dosimetry into clinical studies\nFirst-in-human study design and Phase 0 considerations\nScalable and compliant manufacturing strategies \nThis is the most comprehensive European agenda for targeted radiopharmaceuticals to date\, built to accelerate asset development and address the sector’s most pressing challenges. \nView the full program: https://ter.li/gowcuf \nHyperlink – https://ter.li/gowcuf
URL:http://www.pharmajournalist.com/event/7th-targeted-radiopharmaceuticals-summit-europe/
LOCATION:Mövenpick Hotel Amsterdam City Centre\, Piet Heinkade 11\, Amsterdam\, 1019 BR\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251110
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T044438
CREATED:20250610T104455Z
LAST-MODIFIED:20250610T111651Z
UID:41230-1762732800-1762905599@www.pharmajournalist.com
SUMMARY:Transdermal and Microneedle Drug Delivery
DESCRIPTION:Have you considered how microneedle drug delivery systems could revolutionise the future of vaccine and drug administration? \nThis November\, join SAE Media’s 4th Annual Transdermal and Microneedle Drug Delivery Conference. Engage with leading drug development and delivery experts in a dynamic\, expert-led environment. Connect with forward-thinking innovators to explore cutting-edge case studies\, breakthrough vaccine and therapeutic applications\, and the evolving capabilities of transdermal and microneedle technologies. Transdermal and microneedle patches hold the potential to ‘go beyond the needle’ and transform pharmaceutical development—offering enhanced accessibility and long-term delivery solutions. With applications ranging from improved vaccine distribution to advanced diagnostics\, these technologies are poised to reshape healthcare by increasing efficacy and expanding global access to life-changing treatments. \nTo know more click here.
URL:http://www.pharmajournalist.com/event/transdermal-and-microneedle-drug-delivery-2025/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251109
DTEND;VALUE=DATE:20251112
DTSTAMP:20260515T044438
CREATED:20250613T091742Z
LAST-MODIFIED:20250613T091907Z
UID:41257-1762646400-1762905599@www.pharmajournalist.com
SUMMARY:8th Neuropsychiatric Drug Development Summit
DESCRIPTION:Industry’s Flagship Forum Capturing Advancements Across Discovery\, Preclinical\, Translational\, Clinical & Regulatory Development of Innovative Neuropsychiatric Therapeutics \nUniting 150+ discovery\, preclinical\, translational\, clinical\, and regulatory leaders\, the 8th Neuropsychiatric Drug Development Summit returns to provide you with an unrivaled opportunity to stay attuned to the latest progress while tackling industry’s most pressing challenges across a wide spectrum of mental health indications. \n \nRecognized by key leaders as the “ideal size”\, offering a “targeted audience” perfect for meaningful networking and collaboration\, join thought leaders from Bristol Myers Squibb\, AbbVie\, Otsuka\, Johnson & Johnson\, Biogen\, Lundbeck\, Delix Therapeutics\, Boehringer Ingelheim\, and many more this September to revitalize the mental health drug development landscape. \nOver the 3 day agenda\, you’ll engage in deep-dive interactive workshops\, roundtable discussions\, data-driven presentations and structured networking activities to foster collaboration and gain the latest insights to truly advance your pipeline of next generation neuropsychiatric therapeutics. \nOur attendees span discovery\, in vivo pharmacology\, translational medicine\, clinical development\, medical\, regulatory affairs\, academics\, venture capitalists\, and solution providers\, ensuring that whatever part you play in transforming the mental health treatment and therapeutic landscape\, you are surrounded by peers with the knowledge and capacity to support you. \nWhen you join the Neuropsychiatric Drug Development Summit you can expect to: \n\nDecipher the journey to ‘precision psychiatry’ through investigating the most progressive advancements in EEG and fluid-based markers\nDiscover innovative strategies to control placebo responses and bridge the translational gap to effectively analyze phenotypic behavior preclinically\nInvestigate the efficacy of standalone psychedelics vs when applied in conjunction with psychotherapy\, and explore groundbreaking progress in novel non-hallucinogenic neuroplastogens\nReview the latest advancements in new targets and mechanisms\, including moving beyond atypical antidepressants and antipsychotics\, to truly transform patient burdens\n\nPlus\, all new for 2025 is the EEG Focus Day which will support your efforts in utilizing EEG as a comprehensive and translational tool to guide your program through end-to-end development\, and the new Investor’s Panel which will explore the catalysts driving deal-making momentum in the current neuropsychiatric and mental health R&D landscape. \nSo\, what are you waiting for? Learn more about the summit today and explore the 40+ leading experts presenting at this year’s meeting\, the array of sessions and bespoke workshops designed to support you\, and the companies attending to advance neuropsychiatric therapeutics. \nView the brochure now for all this and more: https://ter.li/g4f9aj
URL:http://www.pharmajournalist.com/event/8th-neuropsychiatric-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251104
DTEND;VALUE=DATE:20251107
DTSTAMP:20260515T044438
CREATED:20250916T110442Z
LAST-MODIFIED:20250916T110506Z
UID:41950-1762214400-1762473599@www.pharmajournalist.com
SUMMARY:LEAP HR: Emerging Biopharma
DESCRIPTION:Funding pressures\, regulatory shifts\, global competition\, and relentless layoffs are redefining the pre-commercial biopharma landscape. In this climate\, agile\, transparent\, and people-first leadership is critical to keeping teams engaged\, culture strong\, and organizations moving forward. \nLEAP HR: Emerging Biopharma is the only meeting built for senior HR leaders in this space. Over three days in Boston this November\, you’ll join peers who understand your challenges\, share proven solutions\, and offer the community support you need to navigate disruption\, adapt with resilience\, and do more with less. \nLeave equipped with fresh strategies to strengthen culture\, re-energize your workforce\, and lead through uncertainty with clarity\, community\, and confidence — ready to take on 2026 and beyond. \nLEAP HR: Emerging Biopharma is a high-energy\, high impact\, fully immersive experience. We like to keep things short\, snappy … and dare we say\, fun? Welcome to a new era of conferences – one defined by case-study driven presentations\, an ultra-niche HR life science community and our unique format\, you will never need to attend any other conference. \nLearn more: https://ter.li/o0nb7o
URL:http://www.pharmajournalist.com/event/leap-hr-emerging-biopharma-2025/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251104
DTEND;VALUE=DATE:20251107
DTSTAMP:20260515T044438
CREATED:20250627T101712Z
LAST-MODIFIED:20250627T101712Z
UID:41418-1762214400-1762473599@www.pharmajournalist.com
SUMMARY:2nd Patient Recruitment in Rare Disease Trials
DESCRIPTION:The rare disease trial landscape stands at a pivotal tipping point. While unprecedented advances in trial design\, digital tools\, and regulatory flexibility are accelerating innovation like never before\, the reality for patients remains stark: over 90% of rare diseases still lack an FDA-approved treatment. For many\, clinical trials represent the only path to care\, yet access remains uneven. Geographic isolation\, diagnostic delays\, and socioeconomic barriers continue to exclude many patients\, especially from underserved communities\, from participating in research. \nAdd to this the small\, dispersed patient populations\, high protocol complexity\, and a shortage of disease-specific expertise\, and it’s clear that traditional recruitment approaches no longer suffice. \nNow in its second year\, the Patient Recruitment for Rare Disease Trials Summit stands as the premier forum dedicated to closing this critical gap. Designed for leaders in Patient Recruitment\, Clinical Operations\, Patient Advocacy\, and Medical Affairs this summit unites innovators reshaping rare disease trial access across the entire patient journey. Over three focused days in Boston\, you’ll explore cutting-edge strategies spanning early patient identification to decentralized\, patient-centric trial models that support participants from diagnosis through to long-term retention. Now is the time to accelerate creative recruitment strategies\, deepen early patient engagement\, and harness innovative technologies to ensure no rare disease patient is left behind in the race for transformative therapies. \nYou’ll join 70+ leaders from companies like Biogen\, Takeda\, Teva Pharmaceuticals\, Genentech\, Tenaya Therapeutics\, and Sarepta Therapeutics\, sharing what’s worked – and what hasn’t – when it comes to recruiting\, retaining\, and supporting rare disease patients through clinical trials. \nWhether you’re running a trial for a rare neurological disorder\, launching a global gene therapy study\, or building support programs around ultra-small populations\, the 2nd Patient Recruitment for Rare Disease Trials Summit is your strategic launchpad. \nTo know more visit: https://ter.li/qxs28b
URL:http://www.pharmajournalist.com/event/2nd-patient-recruitment-in-rare-disease-trials/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251027
DTEND;VALUE=DATE:20251031
DTSTAMP:20260515T044438
CREATED:20250613T093335Z
LAST-MODIFIED:20250613T102703Z
UID:41269-1761523200-1761868799@www.pharmajournalist.com
SUMMARY:8th TPD & Induced Proximity Summit
DESCRIPTION: Returning as the industry’s definitive forum from early discovery to clinical development\, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities\, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development. \nFeaturing key leaders such as Arvinas\, Nurix Therapeutics\, C4 Therapeutics\, and innovative newcomers including Larkspur Bio\, Magnet Biomedicine\, TrimTech Therapeutics\, as well as the co-founders of TPD\, Craig Crews and Ray Deshaies\, this is your ultimate meeting to hear the latest clinical data\, forge strategic relationships\, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need. \nDownload the event guide for full details: https://ter.li/i9k5iz
URL:http://www.pharmajournalist.com/event/8th-tpd-induced-proximity-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251027
DTEND;VALUE=DATE:20251030
DTSTAMP:20260515T044438
CREATED:20250604T112925Z
LAST-MODIFIED:20250805T122256Z
UID:41188-1761523200-1761782399@www.pharmajournalist.com
SUMMARY:13th IMPACCT Real-World Evidence Summit
DESCRIPTION:With CMS introducing new guidance for RWD studies\, the FDA announcing a new RWE Center\, and RWD becoming more accessible\, it is clear that RWE will play an increasingly pivotal role in the drug development lifecycle. But uncertainties still remain for the experts applying RWE. \nReturning to Boston\, the 13th IMPACCT Real-World Evidence Summit is the only industry-focused meeting dedicated to uniting RWE experts to consolidate and optimize their RWE strategies. Join 140+ industry pioneers from top pharma and biotech companies\, as they share real-world case studies\, the latest industry insights\, and transformative strategies to upskill your team with the knowledge to advance your RWE utility. \nFind out more \nWhat Can You Expect? \n\nHear how Pfizer are using AI to refine data quality through optimized data generation\, data pipeline automation\, and data augmentation.\nIdentify key tokenization methods to ensure consistency\, interoperability\, and improved data utility for regulatory and payer decision making with AstraZeneca.\nLearn how Abbvie are empowering their value and evidence teams with timely insights to support market access and strategic planning.\nBuild a centralized evidence strategy that aligns your cross-functional teams and ensures consistent objectives with Otsuka and Ionis Pharmaceuticals.\n\nDiscover the extensive list of sessions\, speakers and case studies in our agenda! \nSeize your opportunity to gain invaluable industry insights\, address challenges and foster connections\, to perfect your data-quality and enhance your RWE approaches.
URL:http://www.pharmajournalist.com/event/13th-impacct-real-world-evidence-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251022
DTEND;VALUE=DATE:20251024
DTSTAMP:20260515T044438
CREATED:20250731T101641Z
LAST-MODIFIED:20250731T101641Z
UID:41595-1761091200-1761263999@www.pharmajournalist.com
SUMMARY:3rd Spatial Biology for Drug Development Summit
DESCRIPTION:The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these challenges within the spatial biology space head-on. \n \nAcross an intensive 2-day agenda\, you’ll explore practical solutions to issues spanning data infrastructure\, multi-omics integration\, standardization\, scalability\, and translation into the clinic. This year’s forum will equip you with the latest data-driven strategies to not only overcome obstacles but to maximize the value of spatial biology for deeper disease insights\, robust target identification\, biomarker discovery\, and more. \nFind out more here: https://ter.li/otrpyk \nSpatial biology is at a turning point. Rapid advances in resolution\, sensitivity\, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments\, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin\, highlight the strong momentum and confidence building across the sector. Yet\, challenges around data standardization\, integration\, scalability\, and cost continue to limit widespread adoption\, particularly among small and mid-sized biopharma companies. \nNo other meeting will give you the chance to connect with 70+ spatial biology experts for *free and take away fresh\, actionable data from AstraZeneca\, Takeda\, AbbVie\, Genentech\, Amgen\, Pfizer\, Johnson & Johnson\, and many more – the exact people you need to meet to move your work forward. \nJoin the spatial biology community (for free) here: https://ter.li/fvnrcc
URL:http://www.pharmajournalist.com/event/3rd-spatial-biology-for-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20260515T044438
CREATED:20250620T105534Z
LAST-MODIFIED:20250620T105629Z
UID:41341-1761004800-1761263999@www.pharmajournalist.com
SUMMARY:7th Gene Therapy Analytical Development Summit
DESCRIPTION:Driving Analytical Excellence from Pre-IND Through BLA for Next-Generation Gene Therapies \nReturning to Boston this October\, the 7th Gene Therapy Analytical Development Summit is the industry’s definitive meeting for advancing assay development and analytical strategy across the gene therapy lifecycle. As gene therapy platforms expand beyond AAV to encompass mRNA\, CRISPR-based modalities\, LNPs\, and novel capsids\, analytical teams must evolve in parallel to meet growing regulatory scrutiny and technical complexity. \nThis summit brings together analytical development\, QC\, and regulatory experts to share practical insights on validating potency assays\, genome integrity\, and advanced characterization tools to ensure product consistency\, safety\, and regulatory readiness from early development through to BLA and commercial launch. \nWith expert contributions from leaders at Beam Therapeutics\, Sarepta\, Astellas\, Spark Therapeutics\, Adverum\, REGENXBIO\, and GenSight Biologics\, attendees will explore real-world solutions to persistent challenges in full or empty capsid quantification\, aggregation profiling\, stability assay design\, and assay transfer into GMP environments. \nFeatured speakers include Johnson Varghese\, Vice President of Analytical Sciences at Beam Therapeutics\, sharing phase-appropriate validation strategies\, and Sue Duan\, Head of Analytical Development at Astellas\, who will discuss genome integrity testing across multiple vector platforms. Also presenting are Uditha DeAlwis of Sarepta Therapeutics and Vanessa Strings-Ufombah from Adverum Biotechnologies\, offering unique perspectives on aligning assay strategies with global regulatory expectations. \nAttendees will gain exposure to cutting-edge techniques including long-read sequencing\, digital PCR\, analytical ultracentrifugation\, and mass photometry\, with a focus on integrating these tools into QC-ready workflows that meet IND\, BLA\, and RMAT requirements. \nWith two technical tracks\, this event delivers unmatched depth across bioassays\, molecular analytics\, and physicochemical characterization\, empowering you to optimize existing platforms or develop robust analytics for new therapeutic modalities. \nWhether refining potency assays\, reducing batch variability\, or preparing for regulatory submission\, this is your opportunity to benchmark with peers and shape the future of gene therapy analytics in 2025 and beyond. \nDownload the Brochure Here for More Information: https://ter.li/wld1o2
URL:http://www.pharmajournalist.com/event/7th-gene-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251007
DTEND;VALUE=DATE:20251010
DTSTAMP:20260515T044438
CREATED:20250624T110339Z
LAST-MODIFIED:20250624T110339Z
UID:41387-1759795200-1760054399@www.pharmajournalist.com
SUMMARY:2nd Raw Materials for Cell & Gene Therapy Summit
DESCRIPTION:Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell & Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory and standards leaders such as Andrew Sarafanov (FDA) and Rebecca Potts (USP)\, as they share the latest thinking on BLA review expectations\, raw material characterization\, and the evolving global standards landscape. \nWith the cell and gene therapy industry facing increasing complexity and supply chain uncertainty\, top innovators from Vertex\, Genentech\, and Bristol Myers Squibb will reveal how they’re reengineering supplier strategies\, through dual sourcing\, co-development\, and rigorous vendor qualification. \nFind out more: https://ter.li/yesw2g \nExplore real-world solutions to qualification challenges and variability risks with insights from Ultragenyx\, Abeona Therapeutics\, and Metagenomi. Through hands-on workshops\, strategic roundtables\, and high-impact networking\, you’ll walk away with the connections and frameworks needed to strengthen your quality programs and stay ahead of regulatory expectations. The time to align\, adapt\, and advance is now.
URL:http://www.pharmajournalist.com/event/2nd-raw-materials-for-cell-gene-therapy-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250929
DTEND;VALUE=DATE:20251002
DTSTAMP:20260515T044438
CREATED:20250717T103452Z
LAST-MODIFIED:20250717T103536Z
UID:41520-1759104000-1759363199@www.pharmajournalist.com
SUMMARY:9th MASH Drug Development Summit
DESCRIPTION:The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a new era\, the race is on to deliver more effective\, patient-centered treatments. \nThis year\, dive into novel mechanisms of action\, non-invasive biomarkers\, and strategic combination and sequential therapies. Hear from experts at Eli Lilly\, Pfizer\, Takeda\, Madrigal\, Akero\, 89 Bio\, and more as they share cutting-edge research and clinical strategies targeting diverse patient populations. \nJoin 60+ MASH scientists and drug developers\, gain critical insights\, and build meaningful collaborations over 10+ hours of dedicated networking. Don’t miss the Pre-Conference Combination & Sequential Therapy Day for a focused deep dive into emerging treatment approaches. \nFind out more now: https://ter.li/d9r0pm
URL:http://www.pharmajournalist.com/event/9th-mash-drug-development-summit/
LOCATION:Hyatt Regency Boston / Cambridge\, 575 Memorial Dr\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250929
DTEND;VALUE=DATE:20251002
DTSTAMP:20260515T044438
CREATED:20250701T122415Z
LAST-MODIFIED:20250701T145003Z
UID:41426-1759104000-1759363199@www.pharmajournalist.com
SUMMARY:LEAP TA: Life Sciences
DESCRIPTION:As 2025 shapes up to be a transformative year for talent acquisition in life sciences\, the 7th LEAP TA: Life Sciences returns to Boston\, MA this September (29 – October 1)\, uniting over 120 senior TA professionals from industry pioneers including Pfizer\, AbbVie\, Bristol Myers Squibb\, Bayer\, Edwards Lifesciences\, The Jackson Laboratory\, and more. \nThis is the only event dedicated entirely to helping biopharma reimagine how they attract\, engage\, and retain top talent in an increasingly complex hiring landscape. In a time of political uncertainty\, evolving regulations\, and rapid scientific advancement\, hiring in life sciences has never been more challenging\, or vital to long-term success. \nOver three high-impact days\, uncover how TA leaders are: \n\nNavigating visa challenges\, DEI pushback\, and new workforce expectations\nLeveraging AI\, redefined employer branding\, and technology to build future-ready teams\nDriving value-driven recruitment in the face of political and market disruption\nAdapting to shifting skills requirements through innovative sourcing strategies\n\nFrom small biotechs to global pharma giants\, this event spotlights real-world case studies and actionable insights from across the industry\, all designed to equip you with the tools to compete for niche\, scientific\, and technical talent in today’s market. \nWhether you’re looking to streamline time-to-fill\, reduce turnover\, or build a more resilient and diverse talent pipeline\, LEAP TA: Life Sciences offers a unique opportunity to step back from day-to-day execution\, connect with your peers\, and rethink what’s possible in TA. \nJoin the most forward-thinking talent acquisition leaders in life sciences to shape the future of hiring in 2025 and beyond.
URL:http://www.pharmajournalist.com/event/leap-ta-life-sciences-2025/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250929
DTEND;VALUE=DATE:20251002
DTSTAMP:20260515T044438
CREATED:20250618T133545Z
LAST-MODIFIED:20250724T113321Z
UID:41299-1759104000-1759363199@www.pharmajournalist.com
SUMMARY:6th Genome Editing Therapeutics Summit
DESCRIPTION:With baby KJ successfully receiving the world’s first personalized CRISPR therapy\, alongside continued innovation across in vivo and base editing\, and rapid ex vivo clinical progress\, the genome editing field stands at a pivotal juncture. \nTo mark this definitive CRISPR milestone\, the 6th Genome Editing Therapeutics Summit returns to Boston to celebrate ongoing progress\, whilst also tackling end-to-end challenges from discovery through to commercial strategy. \nUnite with the industry’s leading minds\, as they advance delivery specificity\, spearhead in vivo editing\, ensure precise targeting\, improve translatability\, and build robust clinical strategies to unlock precise\, durable and safe therapeutics. \nThe 2025 Expert Speaker Line-up Includes: \n\nKiran Musunru\, Professor\, Translational Research\, University of Pennsylvania\nTJ Cradick\, Chief Technology Officer\, HuidaGene Therapeutics\nNageswara Kollu\, Senior Director\, Gene Therapy\, Apellis Pharmaceuticals\nAlexandria Petrusich\, Vice President\, Clinical Science\, Prime Medicine\nBradley Ringeisen\, Executive Director\, Innovative Genomics Institute\nChris Brown\, Vice President\, Discovery\, Metagenomi\nAnjulika Chawla\, Vice President\, Medical Affairs\, Clinical Lead\, Bluebird Bio\n\nAlongside 20+ data-driven presentations\, this year’s program will feature a deep-dive workshop dedicated to the impact of baby KJ\, led by Innovative Genomics Institute\, HuidaGene Therapeutics and the University of Pennsylvania. \nEnsure you are part of the most anticipated gene editing event of the year! \nTo know more visit: https://ter.li/rd7cax
URL:http://www.pharmajournalist.com/event/6th-genome-editing-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250923
DTEND;VALUE=DATE:20250926
DTSTAMP:20260515T044438
CREATED:20250528T075314Z
LAST-MODIFIED:20250528T075314Z
UID:41156-1758585600-1758844799@www.pharmajournalist.com
SUMMARY:7th Exosome-Based Therapeutic Development Summit
DESCRIPTION:Showcasing biopharma innovation in 2025\, the 7th Exosome-Based Therapeutics Development Summit returns to Boston as the industry’s only dedicated forum covering the full exosome development pipeline\, from discovery and optimized characterization to scalable manufacturing and clinical translation. \n \nThis year’s Summit brings together key players from Direct Biologics\, Rion\, Aegle Therapeutics\, Aruna Bio\, EXO Biologics\, and more\, as the field accelerates toward the first-ever exosome and EV approvals. \nAcross three content-packed days\, you’ll gain actionable insights and strategic takeaways to support your journey from early-stage research to commercialization. \nJoin 80+ key exosome and extra-cellular vesicle experts specializing in Exosome Biology\, R&D\, CMC to Business Development for an unrivalled learning and networking opportunity to roadmap the therapeutic efficacy and delivery potential of exosomes and EVs towards commercialization and patients in need. \nDon’t miss the chance to lead this field by driving breakthroughs in regenerative and precision medicine and position your pipeline for success in this rapidly advancing space. \nWant to find out more? Download the Official 2025 Brochure here: https://ter.li/c1jk7p \nTo access tickets & discounts\, follow this link: https://ter.li/pi0pdc
URL:http://www.pharmajournalist.com/event/7th-exosome-based-therapeutic-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250922
DTEND;VALUE=DATE:20250926
DTSTAMP:20260515T044438
CREATED:20250606T105932Z
LAST-MODIFIED:20250606T105932Z
UID:41213-1758499200-1758844799@www.pharmajournalist.com
SUMMARY:15th World Clinical Biomarkers & Companion Diagnostics Summit
DESCRIPTION:Fuelled by industry excitement like the world-first approval of a digital pathology CDx\, the biomarker and diagnostics field continues to surge. \nUniting 600+ precision medicine experts this September\, the 15th World Clinical Biomarkers & Companion Diagnostics Summit returns with a refreshed 4-day\, 3-track\, 50+-speaker program\, ready to facilitate connection-making and knowledge-sharing to bring affordable precision healthcare to patients with unmet need. \n\n600+ attendees from biopharma and diagnostic providers\n50+ precision medicine experts on the speaker faculty\n66+ data-driven presentations spanning the end-to-end of drug-diagnostic co-development\n\nEvent guide: https://ter.li/dr5749 \nRegister (FREE* tickets available for biopharma!): https://ter.li/4zaizd
URL:http://www.pharmajournalist.com/event/15th-world-clinical-biomarkers-companion-diagnostics-summit/
LOCATION:Westin Boston Seaport District\, 425 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250909
DTEND;VALUE=DATE:20250911
DTSTAMP:20260515T044438
CREATED:20250715T155945Z
LAST-MODIFIED:20250715T155945Z
UID:41513-1757376000-1757548799@www.pharmajournalist.com
SUMMARY:2nd ADC & Novel Conjugates Partnering & Investment Summit
DESCRIPTION:Refine your strategy\, sharpen your positioning\, and meet the right partners – all at the most efficient networking event of the ADC conference calendar. \nBack for its second year\, the ADC Partnering & Investment Summit unites 100+ top ADC companies\, pharma leaders\, and investors for hyper-aligned and more efficient business networking.\nUnite with other ADC business development leaders where cutting-edge science meets strategic networking: \n\nConnect directly with decision-makers in a less competitive setting\n\n\nUnderstand how others are positioning themselves to refine your own differentiation\n\n\nGain insights from scientific pioneers shaping the future of ADCs to define your strategic direction\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/2nd-adc-novel-conjugates-partnering-investment-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250909
DTEND;VALUE=DATE:20250912
DTSTAMP:20260515T044438
CREATED:20250620T104212Z
LAST-MODIFIED:20250624T105625Z
UID:41327-1757376000-1757635199@www.pharmajournalist.com
SUMMARY:4th PAT & Real Time Quality Summit
DESCRIPTION:The 4th PAT & Real Time Quality Summit is the leading industry-specific forum for Process Analytical Technology (PAT) professionals in the biotech and pharmaceutical sectors. Taking place at a pivotal time\, with the recent release of USP General Chapter <1037> and anticipated FDA guidelines on PAT due in July 2025\, this summit is tailored to help organizations stay ahead of regulatory shifts and technological advancements. \nBringing together over 80+ PAT experts from leading pharmaceutical companies\, biotechs\, and CDMOs\, the summit will address critical challenges such as high investment costs\, integration with legacy systems\, and data management. Through real-world case studies\, panel discussions\, and strategic roadmaps\, you will explore how PAT is rapidly advancing in areas like biopharmaceuticals\, personalized medicine\, and complex therapies. \nJoin your peers this September to: \n\nBenchmarking strategies with top industry leaders and exploring cutting-edge technologies.\nOvercoming tech transfer challenges for small molecules and complex therapies.\nUnderstanding new FDA guidelines and aligning with GMP compliance.\nDemonstrating ROI and gaining executive buy-in through improved efficiency and reduced batch failures.\nReal-Time Release Testing\, enabling faster timelines while maintaining high quality standards.\n\nYou are guaranteed to leave with actionable insights into PAT integration across the drug development lifecycle—from regulatory updates to real-time release strategies—ensuring smoother approvals\, improved manufacturing processes\, and enhanced product consistency. \nWith speakers from renowned organizations such as AstraZeneca\, GlaxoSmithKline\, and Pfizer\, this summit provides an invaluable platform to exchange ideas\, form collaborations\, and successfully navigate the future of PAT in pharma and biopharma. \nDon’t miss this opportunity to connect with the brightest minds in PAT and help shape the next generation of pharma manufacturing.
URL:http://www.pharmajournalist.com/event/4th-pat-real-time-quality-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250908
DTEND;VALUE=DATE:20250910
DTSTAMP:20260515T044438
CREATED:20250528T153145Z
LAST-MODIFIED:20250528T153258Z
UID:41163-1757289600-1757462399@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices USA
DESCRIPTION:Engage in the Latest Innovations in Wearable Injectors and Connected Devices! SAE Media Group’s 3rd Annual Wearable Injectors and Connected Devices USA Conference returns to Boston on September 8–9\, 2025\, bringing together the latest innovations in connected\, on-body drug delivery. Designed for professionals in injectable drug delivery and digital health\, this two-day event will explore critical advancements in large-volume drug delivery\, digital integration\, and user-centric design. Through real-world case studies and expert-led sessions\, you’ll gain actionable insights into the technologies and strategies shaping the future of combination products. Take part in a unique platform to connect and network with key players across pharma and device development\, from R&D and engineering to human factors and regulatory affairs. Whether you’re optimizing your current portfolio or exploring new drug-device opportunities\, this is your chance to stay ahead in a rapidly evolving field and be part of the conversation to shape its future. \nTo know more click here
URL:http://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-usa-2025/
LOCATION:COURTYARD BY MARRIOTT BOSTON DOWNTOWN\, 275 Tremont St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:marketingteamlondon@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250827
DTEND;VALUE=DATE:20250830
DTSTAMP:20260515T044438
CREATED:20250513T120710Z
LAST-MODIFIED:20250513T120710Z
UID:41063-1756252800-1756511999@www.pharmajournalist.com
SUMMARY:5th Oligonucleotides for CNS Summit
DESCRIPTION:In a year where neurology has overtaken cancer as the number one indication prioritized by oligonucleotide drug developers\, now is the time to stay at forefront of ASO and siRNA innovation. Returning to Boston\, this August\, the 5th Oligonucleotides for CNS Summit unites 100+ biopharma leaders across RNA biology\, oligonucleotide chemistry\, DMPK\, pharmacology\, and platform technology\, to discover the latest advancements in brain delivery\, chemistry\, nonclinical safety and more! \nJoin your peers Alnylam Pharmaceuticals\, Denali Therapeutics\, Genentech\, FDA\, Novo Nordisk\, Regeneron\, Servier\, Stoke Therapeutics\, Ultragenyx Pharmaceutical and more\, to overcome key challenges\, build cross-modality relations\, unpack the latest clinical data and redefine the landscape of oligonucleotide research. \nWhat to Expect: \n\nBenchmark your chemistry and biology innovations with dual-tracked workshops developed for medicinal chemists and neurobiologists\nHear from 10+ new speakers\, including insights from the FDA and companies breaking ground across neuromuscular\, neurodegenerative\, neurodevelopmental and ultra-rare indications\nExplore the next wave of delivery tech\, from TfR1 and AOCs to computational CNS PK/PD modeling and novel RNA editing approaches\n\nCapitalize on the recent ‘oligonucleotide boom\,’ by attending this meeting! \nTo know more visit: https://ter.li/uw2usc
URL:http://www.pharmajournalist.com/event/5th-oligonucleotides-for-cns-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250819
DTEND;VALUE=DATE:20250822
DTSTAMP:20260515T044438
CREATED:20250509T085540Z
LAST-MODIFIED:20250509T085540Z
UID:41058-1755561600-1755820799@www.pharmajournalist.com
SUMMARY:9th IPF Summit
DESCRIPTION:This August\, the 9th IPF Summit returns as the industry’s must attend summit\, providing an essential platform for the entire community to gather and dissect the latest breakthroughs and setbacks\, to shape the future of pulmonary fibrosis drug development. \nBe one of the first to view the agenda here: https://ter.li/moky9n \nA Snapshot of What Awaits You in 2025: \n\nCase Study on the Path to Phase 3 Success: Hear directly from Boehringer Ingelheim’s Susanne Stowasser and Matthew Thomas as they unpack nerandomilast’s journey from discovery through to clinical success\nBrand-New From Setbacks to Solutions Seminar Afternoon: Analyze recent Phase 2 and 3 trial failures from with expert insights from Pfizer and former leaders at Galecto and Galapagos\nNavigating a Shifting Treatment Landscape: Explore how clinical benchmarks are changing and how new therapies must position themselves\, with input from Boehringer Ingelheim\, BMS\, and Insilico Medicine\nEnhancing Preclinical Confidence: Discover what a high-confidence translational package looks like in 2025\, featuring case studies from GSK\, Boehringer Ingelheim\, and others.\n\nIf ever there was a time to invest in this community and a conference\, it’s now. Join us to gain the full spectrum of insight needed to bring better IPF therapies to patients – faster. \nFind all the information needed here: https://ter.li/moky9n
URL:http://www.pharmajournalist.com/event/9th-ipf-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR